Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes

IMPORTANCE: Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) have demonstrated many cardiovascular and kidney function benefits for patients with type 2 diabetes (T2D). However, the results of SGLT-2i use in primary prevention of atrial fibrillation (AF) were inconsistent in clinical trials, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuo, Min, D’Andrea, Elvira, Paik, Julie M., Wexler, Deborah J., Everett, Brendan M., Glynn, Robert J., Kim, Seoyoung C., Patorno, Elisabetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554705/
https://www.ncbi.nlm.nih.gov/pubmed/36219443
http://dx.doi.org/10.1001/jamanetworkopen.2022.35995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554705/
https://www.ncbi.nlm.nih.gov/pubmed/36219443
http://dx.doi.org/10.1001/jamanetworkopen.2022.35995

Ejemplares similares